Telix at EAU 2026

Join Telix in London at the European Association of Urology Congress 2026 (EAU26), Europe’s largest urological event.

This year, Telix’s investigational CAIX-targeted PET imaging agent, TLX250-Px, will feature in a record number of oral presentations, covering renal cancer and a range of other potential solid tumor indications.

These presentations, including real-world data, contribute to a growing body of clinical evidence demonstrating the potential of TLX250-Px to improve diagnostic confidence and inform disease management.

TLX250-Px has not received a marketing authorization in any jurisdiction.

Learn more about Telix’s presence at EAU26 below.

March 13
March 14
March 15
March 16
March 13
Twan van der Werff

Radboud UMC
Impact of [89Zr]Zr-girentuximab (TLX250-Px) PET/CT in patients with renal cell carcinoma on virtual tumor board decision making – an interim analysis

Poster | Orange Area, EGPT 3

March 13 | 11:35 – 11:40 GMT

Abstract ID: P0083

Karolien Goffin

UZ Leuven
Impact of [89Zr]Zr-girentuximab (TLX250-Px) PET/CT versus conventional imaging on clinical decision-making in patients with indeterminate renal masses (ZIRCON-X)

Oral | Blue Area, Victoria 4

March 13 | 15:40 – 15:45 GMT

Abstract ID: A0048

Irene Hübner-Resch

Medical University of Vienna
[89Zr]Zr-girentuximab (TLX250-Px) PET/CT in the non-invasive characterization of indeterminate renal lesions: Initial real-world clinical experience

Oral | Blue Area, Victoria 4

March 13 | 15:30 – 15:35 GMT

Abstract ID: A0046

March 14
Alessandro Larcher

IRCCS San Raffaele Scientific Institute
Exploring the role of carbonic anhydrase IX as diagnostic target in Von-Hippel Lindau Disease: A Phase 2 clinical trial

Oral | Red Area, Room 10

March 14 | 13:40 – 13:45 GMT

Abstract ID: LB018

March 15
Francesco Cei

IRCCS San Raffaele Scientific Institute
First-in-human ex-vivo validation of [89Zr]Zr-girentuximab (TLX250-Px) PET/CT for high-risk renal cancer: Tumor heterogeneity, lymph nodes and metastases

Oral | Blue Area, Victoria 5

March 15 | 11:20 – 11:25 GMT

Abstract ID: A0469

March 16
Dickon Hayne

University of Western Australia
[89Zr]Zr-girentuximab (TLX250-Px) PET/CT in urothelial cancer patients (ZiPUP) – A Phase 1 study of a novel staging modality for urothelial carcinoma

Oral | Blue Area, Victoria 5

March 16 | 13:20 – 13:25 GMT

Abstract ID: A0859